Endocrine system

Human Growth Hormone Drug Market to Gain Due to Easy Accessibility of Raised Healthcare Expenditure: Radiant Insights, Inc.

Retrieved on: 
Wednesday, May 30, 2018

Global Human Growth Hormone Drug Market is segmented on the basis of product type as pill, spray, and injections.

Key Points: 
  • Global Human Growth Hormone Drug Market is segmented on the basis of product type as pill, spray, and injections.
  • Human Growth Hormone drug is a type of drug that stimulates growth, and helps in breeding cells in a human body.
  • Human Growth Hormone Drug Market is segmented on the basis of end user as Private Clinics, Hospitals, and others.
  • Human Growth Hormone Drug Market is segmented on the basis of geographical region as North America, Europe, China, Japan, Southeast Asia, and India.

Human Growth Hormone Drug Market to Gain Due to Easy Accessibility of Raised Healthcare Expenditure: Radiant Insights, Inc.

Retrieved on: 
Wednesday, May 30, 2018

Global Human Growth Hormone Drug Market is segmented on the basis of product type as pill, spray, and injections.

Key Points: 
  • Global Human Growth Hormone Drug Market is segmented on the basis of product type as pill, spray, and injections.
  • Human Growth Hormone drug is a type of drug that stimulates growth, and helps in breeding cells in a human body.
  • Human Growth Hormone Drug Market is segmented on the basis of end user as Private Clinics, Hospitals, and others.
  • Human Growth Hormone Drug Market is segmented on the basis of geographical region as North America, Europe, China, Japan, Southeast Asia, and India.

Chipscreen Biosciences Announces that a Pivotal Phase III Clinical Trial of Chidamide in Combination with Exemestane in Patients with Breast Cancer Reached Primary Endpoint

Retrieved on: 
Tuesday, May 29, 2018

This trial is a randomized, double-blind, placebo controlled study involved postmenopausal patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (ABC) failed to tamoxifen and/or nonsteroidal aromatase inhibitor.

Key Points: 
  • This trial is a randomized, double-blind, placebo controlled study involved postmenopausal patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (ABC) failed to tamoxifen and/or nonsteroidal aromatase inhibitor.
  • Chidamide is a selective HDAC inhibitor with unique epigenetic mechanisms against tumor cell growth, immune escapeand drug resistance.
  • In an exploratory clinical study, it has been demonstrated the encouraging antitumor activity of chidamide in combination with exemestane in HR-positive ABC patients.
  • Breast cancer deaths account for 69,500 cases and breast cancer is the leading cause of cancer deaths among women aged below 45 years old.

ViaCyte to Present at the American Diabetes Association's 78th Scientific Sessions

Retrieved on: 
Friday, May 25, 2018

SAN DIEGO, May 25, 2018 /PRNewswire/ -- ViaCyte, Inc. , a privately-held regenerative medicine company, today announced an oral presentation at the American Diabetes Association's (ADA) 78th Scientific Sessions.

Key Points: 
  • SAN DIEGO, May 25, 2018 /PRNewswire/ -- ViaCyte, Inc. , a privately-held regenerative medicine company, today announced an oral presentation at the American Diabetes Association's (ADA) 78th Scientific Sessions.
  • ViaCyte is developing novel stem cell-derived islet replacement therapies that could transform the way that patients with diabetes manage their disease.
  • Once implanted and matured, these cells are designed to secrete insulin and other pancreatic hormones in response to blood glucose levels.
  • For more information on ViaCyte, please visit www.viacyte.com and connect with ViaCyte on Twitter and Facebook .

American Diabetes Association® Releases Long- and Short-Term Public Policy Recommendations for Improving Insulin Affordability

Retrieved on: 
Thursday, May 24, 2018

ARLINGTON, Va., May 24, 2018 /PRNewswire-USNewswire/ -- Today, the American Diabetes Association (ADA) released its " ADA Public Policy Statement: Insulin Access and Affordability ," (Public Policy Statement) outlining both long- and short-term recommendations for improving insulin affordability.

Key Points: 
  • ARLINGTON, Va., May 24, 2018 /PRNewswire-USNewswire/ -- Today, the American Diabetes Association (ADA) released its " ADA Public Policy Statement: Insulin Access and Affordability ," (Public Policy Statement) outlining both long- and short-term recommendations for improving insulin affordability.
  • The Public Policy Statement follows the " Insulin Access and Affordability Working Group: Conclusions and Recommendations ," white paper (White Paper), published May 8, 2018 in Diabetes Care.
  • More than 30 million Americans have diabetes, and approximately 7.5 million of them rely on life-sustaining insulin, including more than 1.5 million individuals with type 1 diabetes.
  • Insulin is a matter of life and death; there is no alternative medication that can be substituted for insulin.

New Research on the Effect of Body Lotions on Capillary Blood Glucose Measurement - Interference of Hydroquinone-containing Body Lotion with Capillary Glucose Measurement - touchENDOCRINOLOGY

Retrieved on: 
Thursday, May 24, 2018

The reliability of capillary blood glucose measurements is tremendously important for patients' care and follow-up.

Key Points: 
  • The reliability of capillary blood glucose measurements is tremendously important for patients' care and follow-up.
  • Some factors independent of glucose control could however affect readings during ambulatory monitoring of capillary glucose levels in patients with diabetes mellitus.
  • They observed a significant increase (delta [95% confidence interval, CI]: 119.5% [77.4-222.1]) of capillary glucose level immediately after administration of hydroquinone-containing body lotion (p
  • They observed from our study that there were significant variations in capillary blood glucose measurements induced by the use of hydroquinone lotion.

New Research on the Effect of Body Lotions on Capillary Blood Glucose Measurement - Interference of Hydroquinone-containing Body Lotion with Capillary Glucose Measurement - touchENDOCRINOLOGY

Retrieved on: 
Thursday, May 24, 2018

The reliability of capillary blood glucose measurements is tremendously important for patients' care and follow-up.

Key Points: 
  • The reliability of capillary blood glucose measurements is tremendously important for patients' care and follow-up.
  • Some factors independent of glucose control could however affect readings during ambulatory monitoring of capillary glucose levels in patients with diabetes mellitus.
  • They observed a significant increase (delta [95% confidence interval, CI]: 119.5% [77.4-222.1]) of capillary glucose level immediately after administration of hydroquinone-containing body lotion (p
  • They observed from our study that there were significant variations in capillary blood glucose measurements induced by the use of hydroquinone lotion.

Diabetic Nephropathy (Insulin) Market to be Driven by Rising Occurrence of Diabetes and Growing Awareness for Diabetes Treatment: Radiant Insights, Inc.

Retrieved on: 
Thursday, May 24, 2018

Prominent factors that are playing a major role in the growth of Diabetic Nephropathy (Insulin) Market are rising occurrence of diabetes, growing R&D investments in drug discovery, growing awareness for diabetes disease treatment, rising usage of combination therapy and growing advanced healthcare infrastructure all over the world.

Key Points: 
  • Prominent factors that are playing a major role in the growth of Diabetic Nephropathy (Insulin) Market are rising occurrence of diabetes, growing R&D investments in drug discovery, growing awareness for diabetes disease treatment, rising usage of combination therapy and growing advanced healthcare infrastructure all over the world.
  • Type into Diabetic Nephropathy (Insulin) Analogue, Regular Human Diabetic Nephropathy (Insulin), and others classify Diabetic Nephropathy (Insulin) Market.
  • Application into Pre-mix Diabetic Nephropathy (Insulin), Short Acting, Long Acting, Intermediate Acting, and others classify Diabetic Nephropathy (Insulin) Market.
  • Access 109 page research report with TOC on "Diabetic Nephropathy (Insulin) Market" available with Radiant Insights, Inc. @ https://www.radiantinsights.com/research/global-diabetic-nephropathy-ins...
    On the other hand, European regional market accounted for the significant share in terms of value and the second key contributor to the Diabetic Nephropathy (Insulin) Market.

Diabetic Nephropathy (Insulin) Market to be Driven by Rising Occurrence of Diabetes and Growing Awareness for Diabetes Treatment: Radiant Insights, Inc.

Retrieved on: 
Thursday, May 24, 2018

Prominent factors that are playing a major role in the growth of Diabetic Nephropathy (Insulin) Market are rising occurrence of diabetes, growing R&D investments in drug discovery, growing awareness for diabetes disease treatment, rising usage of combination therapy and growing advanced healthcare infrastructure all over the world.

Key Points: 
  • Prominent factors that are playing a major role in the growth of Diabetic Nephropathy (Insulin) Market are rising occurrence of diabetes, growing R&D investments in drug discovery, growing awareness for diabetes disease treatment, rising usage of combination therapy and growing advanced healthcare infrastructure all over the world.
  • Type into Diabetic Nephropathy (Insulin) Analogue, Regular Human Diabetic Nephropathy (Insulin), and others classify Diabetic Nephropathy (Insulin) Market.
  • Application into Pre-mix Diabetic Nephropathy (Insulin), Short Acting, Long Acting, Intermediate Acting, and others classify Diabetic Nephropathy (Insulin) Market.
  • Access 109 page research report with TOC on "Diabetic Nephropathy (Insulin) Market" available with Radiant Insights, Inc. @ https://www.radiantinsights.com/research/global-diabetic-nephropathy-ins...
    On the other hand, European regional market accounted for the significant share in terms of value and the second key contributor to the Diabetic Nephropathy (Insulin) Market.

Female Fertility Rapid Tests - In Vitro Diagnostics Market Analysis and Forecast Model

Retrieved on: 
Tuesday, May 22, 2018

Female Fertility Rapid Tests - In Vitro Diagnostics Market Analysis and Forecast Model is built to better visualize quantitative market trends of Female Fertility Rapid Tests within the In Vitro Diagnostics market.

Key Points: 
  • Female Fertility Rapid Tests - In Vitro Diagnostics Market Analysis and Forecast Model is built to better visualize quantitative market trends of Female Fertility Rapid Tests within the In Vitro Diagnostics market.
  • The Female Fertility Rapid Tests Market is segmented into Follicle Stimulating Hormone (FSH) Rapid Tests and Luteinizing Hormone (LH) Rapid Test; comprising of a dipstick/strip or a card or a cassette or a midstream or a digital device.
  • - Annualized total Female Fertility Rapid Tests market revenue by segment and market outlooks from 2005-2024.
  • - Develop business strategies by understanding the trends shaping and driving the Female Fertility Rapid Tests market.